The biotechnology sector is in focus following reports that AbbVie (ABBV) is nearing an acquisition of Apogee Therapeutics (APGE) valued at nearly $11B, a move that would further strengthen the pharma giant's immunology pipeline.
Against that backdrop, Seeking Alpha's Quant Ratings highlight a number of biotechnology companies that currently rank among the highest-rated stocks in the sector. The ratings are based on a proprietary model that evaluates factors such as valuation, growth, profitability, earnings revisions, and momentum.
Tango Therapeutics (TNGX) leads the group with a Quant Rating of 4.88 and a Strong Buy recommendation. Relay Therapeutics (RLAY) and Veracyte (VCYT) follow with scores of 4.77 and 4.65, respectively. TG Therapeutics (TGTX) and Dianthus Therapeutics (DNTH) round out the top five, with each company also earning a Strong Buy rating.
Praxis Precision Medicines (PRAX), Legend Biotech (LEGN), Neurocrine Biosciences (NBIX), Intellia Therapeutics (NTLA), and Krystal Biotech (KRYS) complete the top 10. All five carry Buy ratings and Quant scores above 4.0.
Seeking Alpha's Quant Ratings are assigned on a scale of 1 to 5, with ratings above 3.5 considered bullish and ratings below 2.5 considered bearish.
Top 10 biotechnology stocks by Seeking Alpha Quant Rating:
Tango Therapeutics, Inc. (TNGX), Quant Rating: 4.88
Relay Therapeutics, Inc. (RLAY), Quant Rating: 4.77
Veracyte, Inc. (VCYT), Quant Rating: 4.65
TG Therapeutics, Inc. (TGTX), Quant Rating: 4.60
Dianthus Therapeutics, Inc. (DNTH), Quant Rating: 4.55
Praxis Precision Medicines, Inc. (PRAX), Quant Rating: 4.39
Legend Biotech Corporation (LEGN), Quant Rating: 4.36
Neurocrine Biosciences, Inc. (NBIX), Quant Rating: 4.29
Intellia Therapeutics, Inc. (NTLA), Quant Rating: 4.26
Krystal Biotech, Inc. (KRYS), Quant Rating: 4.24
Biotech ETFs: (IBB), (XBI), (FBT), (BBH), (PBE), (IDNA), (GNOM), (BIB), and (HELX)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.